Brief: Algernon Enrols First U.S. Patient In Phase 2B/3 Human Study Of Ifenprodil For Treatment Of Covid-19
13/08/2020 14:33
Aug 13 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON ANNOUNCES ENROLLMENT OF FIRST U.S. PATIENT IN
MULTINATIONAL PHASE 2B/3 HUMAN STUDY OF IFENPRODIL FOR TREATMENT
OF COVID-19
* ALGERNON PHARMACEUTICALS INC - IT HAS NOW ENROLLED 26
PATIENTS
SINCE STUDY BEGAN ON AUGUST 5
Source text for Eikon: ID:nGNX3NG633
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement